Site navigation

Navigation

Ovarian cancer - taxanes (replaced by TA55)

Summary

This appraisal has been reviewed and the guidance replaced by Ovarian cancer - paclitaxel (review) (No 55).


Guidance documents

  • No documents found

Implementing this guidance

  • None available

Other information

About this guidance

Technology appraisals TA3

Issued: May 2000

How this guidance was produced

See also:

See this guidance in practice:

Order printed copies of this guidance